antihemophilic factor

(redirected from Advate)
Also found in: Dictionary, Thesaurus, Medical.

antihemophilic factor

[¦an·tē‚hē·mə′fil·ik ‚fak·tər]
(biochemistry)
A soluble protein clotting factor in mammalian blood. Also known as factor VIII; thromboplastinogen.
References in periodicals archive ?
CONTRAINDICATIONS ADVATE is contraindicated in patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product.
Facts About ADVATE Advanced Category of Haemophilia A Treatment - ADVATE (Octocog Alfa Recombinant Coagulation Factor VIII) is approved in Europe and the US for the treatment of bleeding episodes in people with haemophilia A.
In the United States, ADVATE [Antihemophilic Factor (Recombinant) Plasma/AlbuminFree Method] is also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children (0-16 years) with hemophilia A.
The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance risks for new and existing products, such as ADVATE, and other technologies; future actions of regulatory bodies and other governmental authorities; product quality or patient safety concerns leading to product recalls, withdrawals, launch delays, litigation, or declining sales; future actions of governmental authorities and other third parties as U.
About ADVATE ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency or classic hemophilia) for:
Approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration.
Upon approval, BAX 855 is expected to be produced at the company's Singapore manufacturing facility, one of several sites currently approved for ADVATE production.
ADVATE is also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children (0-16 years) with hemophilia A.
The recent developments in the respective field include gene therapy for treating hemophilia B, half life extension of the recombinant coagulation factors, development of 4-factor PCC for reversal of vitamin K antagonist anticoagulant therapy along with recent approval of ADVATE in China apart from other clinical trials on run.
Detailed Important Risk Information for ADVATE CONTRAINDICATIONS ADVATE is contraindicated in patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product.